What do systematic reviews say?

Nebulized budesonide vs viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Low

Esomeprazole vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

The review found no eligible studies for this question.

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Omeprazole vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Omeprazole vs ranitidine

The review found no eligible studies for this question.

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fecal microbiota transplantation vs control

Fecal microbiota transplantation showed no clear difference in induction of endoscopic remission in UC at longest compared with control (low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.45 [0.64, 3.29]
  5 studies · 285 participants
  Low

Fecal microbiota transplantation vs control

It is very uncertain whether fecal microbiota transplantation changes maintenance of endoscopic remission in UC (RR > 1 favors FMT) compared with control (very low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 3.28 [0.73, 14.74]
  2 studies · 71 participants
  Very low

Oral 5‐ASA vs SASP

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Once daily dosing vs conventional dosing

Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).

• Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 1.02 [0.98, 1.07]
  1 study · 817 participants
  High

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral 5‐ASA vs placebo

Oral 5‐ASA probably leads to lower failure to induce endoscopic remission compared with placebo (moderate certainty).

• Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 0.77 [0.67, 0.89]
  4 studies · 1154 participants
  Moderate

Oral 5‐aminosalicylic acid vs placebo

Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).

• Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 0.68 [0.61, 0.76]
  8 studies · 1555 participants
  High

Once daily dosing vs conventional dosing

Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).

• Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 0.94 [0.88, 1.01]
  10 studies · 3910 participants
  High

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).

• Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 1.08 [0.91, 1.28]
  6 studies · 707 participants
  Low

Oral 5‐aminosalicylic acid vs sulfasalazine

Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).

• Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 1.14 [1.03, 1.27]
  12 studies · 1655 participants
  High